Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Nebius Group NV (NBIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Nebius Group NV — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B), while Nebius Group NV trades at $180.04 (market cap $56.24B). The key difference: Nebius Group NV is the larger of the two by market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while Nebius Group NV pays none. Which is the better fit depends on your goals.
| GEHC | NBIS | |
|---|---|---|
Market Cap | $31.07B | $56.24B |
Volume | 3,443,020 | 17,483,721 |
Sector | Health | Technology |
52-Week High | $88.16 | $286.69 |
52-Week Low | $59.48 | $73.87 |
Enterprise Value | $39.53B | $58.36B |
Dividend Yield | 0.23% | — |
Typical Hold Time | — | 25 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
NBIS trades at $206.86, down 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows high valuation ratios (P/E 795.62, P/S 42.26) against modest profitability (net margin 3.13%, ROE 0.6%). Recent news highlights AI infrastructure growth potential but also insider selling and competitive risks.
Analyst consensus remains bullish with 82% buy ratings and a $288.67 price target, suggesting 40% upside. Key risks include high capital expenditure, negative cash flow from investing, and dependence on AI demand sustainability. The stock's outlook hinges on execution of its $37B backlog and GPU rental pricing trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →
